drugset / Trial / NCT01418729

Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma

NCT01418729

Phase 2 Completed 216 enrolled Hospital Donostia INSTITUTO BIODONOSTIA · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the overall survival (OS) in order to assess the efficacy and safety of pravastatin as adjuvant treatment to sorafenib.

Timeline

Start
2011-09
Primary completion
2015-12
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pravastatin Small molecule 40 mg